111. Immunotherapy for metastatic non-small cell lung cancer : real-world data from an academic Central and Eastern European centerMarija Ivanović, Lea Knez, Ana Herzog, Mile Kovačević, Tanja Čufer, 2021, izvirni znanstveni članek Povzetek: Background. Immunotherapy with immune checkpoint inhibitors (ICIs) recently became the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). Here, we present the first results of a real-world observational study on the effectiveness of ICI monotherapy in patients with advanced NSCLC treated at a single academic center in a Central and Eastern European (CEE) country. Materials and methods. Overall, 66 consecutive patients with advanced NSCLC treated with ICIs in everyday clinical practice, either with first-line pembrolizumab (26 patients) or second-line atezolizumab, nivolumab, or pembrolizumab (40 patients), from August 2015 to November 2018, were included. All data were retrieved from a hospital lung cancer registry, in which the data is collected prospectively. Results. Included patients had a median age of 64 years, most were male (55%), 6% were in performance status >/=2, and 18% had controlled central nervous system metastases at baseline. In first-line, the median progression-free survival (mPFS) was 9.3 months, while the median overall survival (mOS) was not reached. The 1-year overall survival (OS) was 62%. In second-line, the mPFS and mOS were 3.5 months and 9.9 months, respectively, with a 1-year OS of 35%. In the overall population, adverse events of any grade were recorded in 79% of patients and of severe grade (3-4) in 12% of patients. Conclusion. The first real-world outcomes of NSCLC immunotherapy from a CEE country suggest comparable effectiveness to those observed in clinical trials and other real-world series, mainly coming from North America and Western European countries. Further data to inform on the real-world effectiveness of immunotherapy worldwide are needed.
Ključne besede: non-small cell lung carcinoma, immunotherapy, advanced non-small cell lung cancer, real-world data, Central Europe, Europe, Eastern Europe
Objavljeno v DiRROS: 12.10.2021; Ogledov: 957; Prenosov: 292
 Povezava na datoteko |
112. Priporočila Onkološkega inštituta za zdravljenje bolnikov z adenokarcinomom želodca2021, druge monografije in druga zaključena dela Povzetek: V Sloveniji vsako leto zboli zaradi raka želodca okrog 450 bolnikov, od tega ima tri četrtine bolnikov ob postavitvi diagnoze razširjeno ali razsejano bolezen. Zato je pomembno, da imamo razvito sodobno multidisciplinarno zdravljenje. Onkološki inštitut je na poti pridobitve evropske onkološke akreditacije, ki jo podeljuje priznana Evropska organizacija onkoloških inštitutov (OECI), katere član je tudi Onkološki inštitut Ljubljana. Namen tega projekta je razvoj kliničnih poti, ki bodo omogočile celostno obravnavo bolnikov z rakom. Slovenskih priporočil za zdravljenje adenokarcinoma želodca trenutno nimamo, zato smo bili primorani sprejeti te, ki jim bomo sledili na Onkološkem inštitutu. V teh priporočilih, zaradi drugačne narave bolezni, ni zajeto zdravljenje raka ezofagogastričnega stika.
Ključne besede: rak želodca, adenokarcinom, onkološko zdravljenje, priporočila
Objavljeno v DiRROS: 14.09.2021; Ogledov: 1439; Prenosov: 376
 Celotno besedilo (983,68 KB) |
113. Prenamnožitev osmerozobega in šesterozobega smrekovega lubadarja v Sloveniji v 2021Nikica Ogris, Marija Kolšek, 2020, kratki znanstveni prispevek Ključne besede: Ips typographus, Pityogenes chalcographus, prenamnožitev, navadna smreka, Picea abies, osmerozobi smrekov lubadar, šesterozobi smrekov lubadar, lokacija, populacija, gostota, model, RITY-2, CHAPY-1
Objavljeno v DiRROS: 23.07.2021; Ogledov: 1001; Prenosov: 501
Celotno besedilo (956,94 KB) |
114. |
115. |
116. Predlogi za pravno ureditev področja upravljanja s smrekovimi podlubnikiNikica Ogris, Andreja Kavčič, Marija Kolšek, Maarten De Groot, 2021, elaborat, predštudija, študija Ključne besede: Ips typographus, pravilnik o varstvu gozdov, osmerozobi smrekov lubadar, pasti, skladišča gozdnih lesnih sortimentov, monitoring, zatiranje, optimizacija
Objavljeno v DiRROS: 29.06.2021; Ogledov: 896; Prenosov: 0 |
117. Na kaj moramo biti pozorni, ko izbiramo feromonski pripravek za ulov osmerozobega smrekovega lubadarja v režaste pasti?Nina Šramel, Andreja Kavčič, Marija Kolšek, Maarten De Groot, 2021, kratki znanstveni prispevek Ključne besede: gozdovi, varstvo gozdov, Ips typographus, feromonski pripravki, analiza učinkovitosti, podlubniki, ulov lubadarja, indeks učinkovitosti
Objavljeno v DiRROS: 18.05.2021; Ogledov: 1271; Prenosov: 881
Celotno besedilo (874,46 KB)
Gradivo ima več datotek! Več... |
118. |
119. |
120. |
